Држава: Велика Британија
Језик: Енглески
Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)
Bivalirudin
The Medicines Company UK Ltd
B01AE06
Bivalirudin
250mg
Powder for solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 02080100
1 B. PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE USER ANGIOX 250 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INJECTION OR INFUSION bivalirudin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - If you get any side effects talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Angiox is and what it is used for 2. What you need to know before you use Angiox 3. How to use Angiox 4. Possible side effects 5. How to store Angiox 6. Contents of the pack and other information 1. WHAT ANGIOX IS AND WHAT IT IS USED FOR Angiox contains a substance called bivalirudin which is an antithrombotic medicine. Antithrombotics are medicines which prevent the formation of blood clots (thrombosis). Angiox is used to treat patients : with chest pain due to heart disease (acute coronary syndromes - ACS) who are having surgery to treat blockages in their blood vessels (angioplasty and/or percutaneous coronary intervention - PCI). 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ANGIOX DO NOT USE ANGIOX - if you are allergic to bivalirudin or any of the other ingredients of this medicine (listed in section 6) or hirudins (other blood thinning medicines). - if you have, or have recently had, any bleeding from your stomach, intestines, bladder or other organs, for example, if you have noticed abnormal blood in your stools or urine (except from menstrual bleeding). - if you have, or have had, difficulty with your blood clotting (a low platelet count). - if you have severe high blood pressure. - if you have an infection of the heart tissue. - if you have severe kidney problems or if you need kidney dialysis. Check with the doctor if you are unsure. WARNINGS AND PRECAUTIONS Talk to your doctor before using Angiox. if bleeding occurs (if this happens, treatment with Angiox w Прочитајте комплетан документ
OBJECT 1 ANGIOX 250MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INJECTION OR INFUSION Summary of Product Characteristics Updated 03-Nov-2016 | The Medicines Company UK Ltd 1. Name of the medicinal product Angiox 250 mg powder for concentrate for solution for injection or infusion. 2. Qualitative and quantitative composition Each vial contains 250 mg bivalirudin. After reconstitution 1 ml contains 50 mg bivalirudin. After dilution 1 ml contains 5 mg bivalirudin. For the full list of excipients see section 6.1. 3. Pharmaceutical form Powder for concentrate for solution for injection or infusion (powder for concentrate). White to off-white lyophilised powder. 4. Clinical particulars 4.1 Therapeutic indications Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Angiox should be administered with acetylsalicylic acid and clopidogrel. 4.2 Posology and method of administration Angiox should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures. Posology _Patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) _ _undergoing primary PCI _ The recommended dose of bivalirudin for patients undergoing PCI is an intravenous bolus of 0.75 mg/kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/kg body weight/hour for at least the duration of the procedure. The infusion of 1.75 mg/kg body weight/hour may be continued for up to 4 hours post-PCI and at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 – 12 hours as clinically necessary. In STEMI patients the infusion of 1.75 mg/kg body weight/hour should be continued for up to 4 hours post-PCI and c Прочитајте комплетан документ